JP Morgan Chase
AARD

JP Morgan Chase’s Aardvark Therapeutics AARD Stock Holding History

JP Morgan Chase’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.24K Sell
1,784
-4,833
-73% -$22.6K ﹤0.01% 6940
2026
Q1 		$24.1K Sell
6,617
-266
-4% -$2.76K ﹤0.01% 6484
2025
Q4 		$90.3K Buy
6,883
+4,567
+197% +$57K ﹤0.01% 5941
2025
Q3 		$30.8K Sell
2,316
-361
-13% -$4.07K ﹤0.01% 6381
2025
Q2 		$36.2K Sell
2,677
-423
-14% -$4.36K ﹤0.01% 6031
2025
Q1 		$23.3K Buy
+3,100
New +$34.8K ﹤0.01% 6106

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

JP Morgan Chase's AARD Position: Q2 2026 in Review

JP Morgan Chase reduced its Aardvark Therapeutics (AARD) stake by 73% in Q2 2026, selling an estimated $22.6K and leaving 1,784 shares worth $9.24K. The position accounts for ﹤0.01% of the portfolio, ranked #6940.

JP Morgan Chase first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $90.3K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • JP Morgan Chase held 1,784 shares of Aardvark Therapeutics worth $9.24K as of Q2 2026.
  • JP Morgan Chase sold 4,833 Aardvark Therapeutics shares in Q2 2026, an estimated $22.6K.
  • Aardvark Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6940 holding.
  • JP Morgan Chase first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • JP Morgan Chase's Aardvark Therapeutics position peaked at $90.3K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.